Source | Evidence on protein | Close homologs |
---|---|---|
Cuervo et al. | no | yes: 0 |
Hassani et al. | no | yes: 0 |
Forrest at al. (metacyclic) | no | yes: 0 |
Forrest at al. (procyclic) | no | yes: 0 |
Silverman et al. | no | yes: 0 |
Pissara et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Pires et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Silverman et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Jamdhade et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
DeepLoc | ||
SignalP6 | no | yes: 0, no: 10 |
NetGPI | no | yes: 0, no: 10 |
Term | Name | Level | Count |
---|---|---|---|
GO:0005737 | cytoplasm | 2 | 6 |
GO:0005929 | cilium | 4 | 6 |
GO:0042995 | cell projection | 2 | 6 |
GO:0043226 | organelle | 2 | 6 |
GO:0043227 | membrane-bounded organelle | 3 | 6 |
GO:0110165 | cellular anatomical entity | 1 | 6 |
GO:0120025 | plasma membrane bounded cell projection | 3 | 6 |
Related structures:
AlphaFold database: A4HNB6
Leishmania | From | To | Domain/Motif | Score |
---|---|---|---|---|
CLV_PCSK_SKI1_1 | 124 | 128 | PF00082 | 0.253 |
DEG_Nend_UBRbox_3 | 1 | 3 | PF02207 | 0.600 |
DEG_SCF_TRCP1_1 | 148 | 154 | PF00400 | 0.467 |
DOC_USP7_MATH_1 | 46 | 50 | PF00917 | 0.533 |
DOC_USP7_MATH_1 | 86 | 90 | PF00917 | 0.506 |
DOC_WW_Pin1_4 | 101 | 106 | PF00397 | 0.536 |
LIG_14-3-3_CanoR_1 | 110 | 118 | PF00244 | 0.457 |
LIG_CSL_BTD_1 | 4 | 7 | PF09270 | 0.422 |
LIG_FHA_1 | 112 | 118 | PF00498 | 0.414 |
LIG_FHA_1 | 26 | 32 | PF00498 | 0.435 |
LIG_FHA_1 | 39 | 45 | PF00498 | 0.496 |
LIG_FHA_1 | 93 | 99 | PF00498 | 0.384 |
LIG_FHA_2 | 51 | 57 | PF00498 | 0.496 |
LIG_LIR_Apic_2 | 100 | 105 | PF02991 | 0.521 |
LIG_LIR_Apic_2 | 163 | 169 | PF02991 | 0.454 |
LIG_LIR_Gen_1 | 125 | 134 | PF02991 | 0.470 |
LIG_LIR_Gen_1 | 39 | 50 | PF02991 | 0.487 |
LIG_LIR_Nem_3 | 120 | 126 | PF02991 | 0.499 |
LIG_LIR_Nem_3 | 137 | 142 | PF02991 | 0.467 |
LIG_LIR_Nem_3 | 39 | 45 | PF02991 | 0.487 |
LIG_SH2_CRK | 109 | 113 | PF00017 | 0.518 |
LIG_SH2_CRK | 139 | 143 | PF00017 | 0.602 |
LIG_SH2_CRK | 68 | 72 | PF00017 | 0.386 |
LIG_SH2_STAT5 | 116 | 119 | PF00017 | 0.437 |
LIG_TRAF2_1 | 97 | 100 | PF00917 | 0.444 |
MOD_CK1_1 | 23 | 29 | PF00069 | 0.534 |
MOD_CK1_1 | 93 | 99 | PF00069 | 0.521 |
MOD_CK2_1 | 50 | 56 | PF00069 | 0.475 |
MOD_CK2_1 | 67 | 73 | PF00069 | 0.432 |
MOD_GlcNHglycan | 11 | 14 | PF01048 | 0.329 |
MOD_GlcNHglycan | 145 | 151 | PF01048 | 0.553 |
MOD_GlcNHglycan | 163 | 166 | PF01048 | 0.444 |
MOD_GlcNHglycan | 48 | 51 | PF01048 | 0.253 |
MOD_GlcNHglycan | 95 | 98 | PF01048 | 0.396 |
MOD_GSK3_1 | 20 | 27 | PF00069 | 0.563 |
MOD_GSK3_1 | 46 | 53 | PF00069 | 0.540 |
MOD_GSK3_1 | 86 | 93 | PF00069 | 0.574 |
MOD_PIKK_1 | 20 | 26 | PF00454 | 0.453 |
MOD_Plk_1 | 38 | 44 | PF00069 | 0.530 |
MOD_Plk_1 | 55 | 61 | PF00069 | 0.418 |
MOD_Plk_1 | 86 | 92 | PF00069 | 0.496 |
MOD_Plk_4 | 1 | 7 | PF00069 | 0.648 |
MOD_Plk_4 | 112 | 118 | PF00069 | 0.485 |
MOD_Plk_4 | 67 | 73 | PF00069 | 0.430 |
MOD_Plk_4 | 86 | 92 | PF00069 | 0.530 |
MOD_ProDKin_1 | 101 | 107 | PF00069 | 0.536 |
MOD_SUMO_rev_2 | 120 | 126 | PF00179 | 0.453 |
MOD_SUMO_rev_2 | 96 | 105 | PF00179 | 0.401 |
TRG_DiLeu_BaEn_2 | 124 | 130 | PF01217 | 0.384 |
TRG_ENDOCYTIC_2 | 109 | 112 | PF00928 | 0.515 |
TRG_ENDOCYTIC_2 | 123 | 126 | PF00928 | 0.562 |
TRG_ENDOCYTIC_2 | 139 | 142 | PF00928 | 0.598 |
TRG_ENDOCYTIC_2 | 62 | 65 | PF00928 | 0.446 |
TRG_ENDOCYTIC_2 | 68 | 71 | PF00928 | 0.437 |
TRG_Pf-PMV_PEXEL_1 | 140 | 144 | PF00026 | 0.428 |
Protein | Taxonomy | Sequence identity | Coverage |
---|---|---|---|
A0A0N1ICH3 | Leptomonas seymouri | 46% | 88% |
A0A0S4JM98 | Bodo saltans | 30% | 100% |
A0A1X0P624 | Trypanosomatidae | 29% | 100% |
A0A3Q8IQ44 | Leishmania donovani | 71% | 89% |
A0A422P1B2 | Trypanosoma rangeli | 35% | 100% |
A4IBY8 | Leishmania infantum | 71% | 89% |
C9ZYL7 | Trypanosoma brucei gambiense (strain MHOM/CI/86/DAL972) | 29% | 100% |
E9AFS5 | Leishmania major | 63% | 100% |
E9B6X7 | Leishmania mexicana (strain MHOM/GT/2001/U1103) | 73% | 89% |